Pfizer (PFE) Begins Study on RSV Vaccine in Older Adults

Published on September 3, 2021

Pfizer (PFE) starts a phase III study which will evaluate its respiratory syncytial virus vaccine candidate, RSVpreF in adults aged 60 years and above...

Continue reading on website
Other news

Is Splunk a Good Data Analytics Stock to Invest In?

September 3, 2021
Software company Splunk (SPLK) boasts an impressive customer base and increased its cloud revenue in its latest quarter. However, is it wise to bet on...

Miners Investing in Autonomous Operations to Improve Efficiency

September 3, 2021
Miners like BHP, VALE, RIO and NEM are investing in technology for improved front-line safety, increased production levels and efficiency while loweri...